Neurocognitive effects of chemotherapy and endocrine therapies in the treatment of breast cancer: Recent perspectives

Cancer Investigation

Volumn 30, Issue 2, 2012, Pages 135-148

  Walker, Caroline H ^a   Drew, Barbara A ^a   Antoon, James W ^a   Kalueff, Alan V ^a   Beckman, Barbara S ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Chemobrain; Cognitive impairment; Pharmacology, Chemotherapy

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; EPIRUBICIN; ESTROGEN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; MITOXANTRONE; PACLITAXEL; TAMOXIFEN; THIOTEPA;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; COGNITION; COGNITIVE DEFECT; ESTROGEN ACTIVITY; ESTROGEN BLOOD LEVEL; GENETIC POLYMORPHISM; HUMAN; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REGULATORY MECHANISM; TELOMERE SHORTENING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COGNITION DISORDERS; FEMALE; HUMANS; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES;

EID: 84856098600     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.636116     Document Type: Article

References (131)

1. Jemal A, Siegel R, Ward, E,Hao Y, Xu J, ThunM. Cancer Statistics, 2009. CA Cancer J Clin 2009;59(4):225-249.
2. United States. Cancer Care Issues in the United States: Quality of Care, Quality of Life. Bethesda, Md: National Cancer Program, National Cancer Institute, 1998.
3. Ferrell B,HasseyDK.Qualityof life among long-termcancer survivors. Oncology 1997;11:565-576.
4. Morse R, Rodgers J, Verrill M, Kendell K. Neuropsychological functioning following systemic treatment in women treated for breast cancer: A review. Eur J Cancer 2003;39:2288-2297. (Pubitemid 37214852)
5. Cancer Facts and Figures 2010. Atlanta, GA: American Cancer Society.
6. WienekeMH, Dienst ER.Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 1995;4:61-66. (Pubitemid 26093776)
7. van Dam FS, Schagen SB, Muller MJ, Boogerd W, Wall E, Droogleever FortuynME, Rodenhuis S. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high dose versus standard-dose chemotherapy. J Natl Cancer I 1998;90:210-218. (Pubitemid 28114539)
8. Wefel JS, Lenzi R,Theiault R, Buzdar AU, Cruickshank S, Meyers CA. Chemobrain in breast carcinoma? A prologue. Cancer 2004;101:466-475.
9. Donovan KA, Small BJ, AndrykowskiMA, Schmitt FA,Munster P, Jacobsen PB. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer 2005;104:2499-2507. (Pubitemid 41691574)
10. Jenkins V, Shilling V, Deutsch G, Bloomfield D, Morris R, Allan S, Bishop H, Hodson N, Mitra S, Sadler G, Shah E, Stein R, Whitehead S, Winstanley J. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Brit J Cancer 2006;94:828-834.
11. Ahles TA, Saykin AJ. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer 2002;3(Suppl 3):S84-S90.
12. Ferguson RJ, Ahles TA. Low neuropsychological performance among adult cancer survivors treated with chemotherapy. Curr Neurol Neurosci Rep 2003;3:215-222. (Pubitemid 38899005)
13. Ahles T, Saykin A, Furstenberg CT, Cole B, Mott LA, Skalla K, WhedonMB, Bivens S, Mitchell T, Greenburg ER, Silberfarb PM. Neuropsychologic impact of standard-dose systemic chemotherapy in long-termsurvivors of breast cancer and lymphoma. JClin Oncol 2002;20:485-493. (Pubitemid 34072533)
14. Tannock IF, Ahles TA, Ganz PA, van Dam FS. Cognitive impairment associated with chemotherapy for cancer: Report of a workshop. J Clin Oncol 2004;22:2233-2239. (Pubitemid 41095159)
15. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapyinduced cognitive changes. Nat. Rev. Cancer 2007;7:192-201.
16. Weiss B. Chemobrain: A translational challenge for neurotoxicology. Neuro Toxicology 2008;29:891-898.
17. Brezden C, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000;18:2695-2701. (Pubitemid 30463551)
18. Castellon SA, Ganz PA, Bower JE, Petersen L,AbrahamL,Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsy 2004;26:955-969. (Pubitemid 39577316)
19. Phillips KA, Bernhard J. Adjuvant breast cancer treatment and cognitive function: Current knowledge and research directions. J Natl Cancer I 2003;95:190-197. (Pubitemid 36240631)
20. Poppelreuter RC, Mannes AJ, Clark US, Bennett GJ. Cognitive dysfunction and subjective complaints of cancer patients: A cross-sectional study in a cancer rehabilitation centre. Eur J Cancer 2004;40:43-49.
21. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999;85: 640-650. (Pubitemid 29075285)
22. Mehnert A, Scherwath A, Schirmer L, Schleimer B, Petersen C, Schulz-Kindermann F, Zander AR, Koch U. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns 2007;66:108-118. (Pubitemid 46366616)
23. Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: An international perspective fromthe Venice cognitive workshop. AnnOncol 2008;19:623-629. (Pubitemid 351461030)
24. Saykin AJ, Ahles TA, McDonald BC. Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsy 2003; 8(4):201-216. (Pubitemid 37474731)
25. Stemmer SM, Stears JC, Burton BS, Jones RB, Simon JH. White matter changes in patients with breast cancer treated with ighdose chemotherapy and autologous bonemarrow support. AJNR Am J Neuroradiol 1994;15:1267-1273. (Pubitemid 24257853)
26. Inagaki M, Yoshikawa E, Matsuoka Y, Sugawara Y, Nakano T, Akechi T,Wada N, Imoto S, Murakami K, Uchitomi Y. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 2007;109:146-156. (Pubitemid 46120202)
27. Saykin AJ, McDonald BC, Ahles TA. Alterations in brain activation during workingmemory in patients with breast cancer: Relation to treatment modality, cancer status and task performance. In 13th Annual Meeting of the Organization for Human Brain Mapping. Neuroimage: Chicago, IL, 2007; pp 36 (Suppl 86).
28. Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA. Brain structure and function difference in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol 2007;25:3866-3870. (Pubitemid 47477262)
29. Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, Waddell K, Petersen L, Phelps ME, Ganz PA. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Tr 2007;103:303-311. (Pubitemid 46944511)
30. Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, Ryan CM. Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology 2006;15:422-430. (Pubitemid 43826855)
31. Ahles T, Saykin A, McDonald B, Furstenberg C, Cole B, Hanscom B, Mulrooney T, Schwartz G, Kaufman P. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Tr 2008;110:143-152. (Pubitemid 351793851)
32. Hermelink K, Untch M, Lux MP, Kreienberg R, Beck T, Bauerfeind I, Munzel K. Cognitive function during neoadjuvant chemotherapy for breast cancer: Results of a prospective, multicenter, longitudinal study. Cancer 2007;109: 1905-1913. (Pubitemid 46668557)
33. Jansen CE, Miaskowski C, Dodd M, Dowling G, Kramer J. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 2005;104:2222-2233. (Pubitemid 41579970)
34. Schagen SB, Muller MJ, Boogerd W, Rosenbrand RM, van Rhijn D, Rodenhuis S, van Dam FSAM. Late Effects of adjuvant chemotherapy on cognitive function: A follow-up study in breast cancer patients. Ann Oncol 2002;13:1387-1397.
35. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acutemyelogenous leukemia or myelodysplastic syndrome. Cancer 2005;104:788-793. (Pubitemid 41113679)
36. Ahles TA, Silberfarb PM, Herndon J, Maurer LH, Kornblith AB, Aisner J, Perry MC, Eaton WL, Zacharski LL, Green MR, Holland JC. Psychological and neuropsychological functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin, a study for Cancer and Leukemia Group B. J Clin Oncol 1998;16:1954-1960.
37. WisePM. Estrogen therapy: Does it helpor hurt the adult and the aging brain? Insights derived fromanimal models. Neuroscience 2006;138:831-835.
38. Turgeon JL, Carr MC, Maki PM, Mendelsohn ME, Wise PM. Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: Insights from basic science and clinical studies. Endocr Rev 2006;27:575-605. (Pubitemid 44582052)
39. Bender CM, Paraska KK, Sereika SM, Ryan CM, Berga SL. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: A critical review. J Pain Symptom Manag 2001;21:407-424. (Pubitemid 32452141)
40. Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, Hsia J, Margolis KL, Hogan PE, Wallace R, Dailey M, Freeman R, Hays J, for the Women's Health InitiativeMemory, S. Conjugated equine estrogens and global cognitive function in postmenopausal women: women's health initiative memory study. JAMA 2004;291:2959-2968. (Pubitemid 38802685)
41. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass MLS, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: The women's health initiative memory study: A randomized controlled trial. JAMA 2003;289:2663-2672. (Pubitemid 37430137)
42. Chen D, Chun FU, Shi B, Xu YM. Tamoxifen and toremifene cause impairment of learning and memory function in mice. Pharmacol Biochem Behav 2002;71:277-284. (Pubitemid 34102488)
43. Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Tr 2000;64:165-176. (Pubitemid 32010334)
44. Bender CMP, Sereika SMP, BrufskyAMMDP, Ryan CMP, Vogel VGMDM. HS, Rastogi PMD, Cohen SMP, Casillo FEBSN, Berga SLMD. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause 2007;15:995-998.
45. Schilder CM, Seynaeve C, Beex LV, BoogerdW, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: Results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 2010;28:1294-1300.
46. Phillips K-A, Ribi K, Sun Z, Stephens A, Thompson A, Harvey V, Tḧurlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, PriceKN,Gelber RD, Bernhard J.Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast 2010;19(5):388-395.
47. Ginos JZ, Cooper AJ, Dhawan V, Lai JC, Strother SC, Alcock N, Rottenberg DA. [13N]cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. J Nucl Med 1987;28:1844-1852. (Pubitemid 18017095)
48. Dietrich J, Han R, Yang Y, Mayer-Proschel M, Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006;5:22.
49. Olivi A, Gilbert M, Duncan KL, Corden B, Lenartz D, Brem H. Direct delivery of platinum-based antineoplastics to the central nervous system: A toxicity and ultrastructural study. Cancer Chemother. Pharmacol. 1993;31:449-454. (Pubitemid 23093316)
50. El-Shazly MO, Afify MMH, El-Dieb MK. Histopathological study into side-effect toxicity of some drugs used in treatment of cancer. Arch. Exp. Vet. Med. 1989;43:319-326.
51. ClarkAW, Parhad IM,Griffin JW, PriceDL.Neurotoxicity of cisplatinum: pathology of the central and peripheral nervous systems. Neurology 1980;30:429.
52. Troy L, McFarland K, Littman-Power S, Kelly BJ, Walpole ET, Wyld D. Cisplatin-based therapy: A neurological and neuropsychological review. Psycho-Oncology 2000;9:29-39. (Pubitemid 30110388)
53. von Zglinicki T, Martin-Ruiz CM. Telomeres as biomarkers for ageing and age-related diseases. Curr Mol Med 2005;5: 197-203. (Pubitemid 40601647)
54. Maccormick RE. Possible acceleration of aging by adjuvant chemotherapy: A cause of early onset frailty? Med Hypotheses 2006;67:212-215. (Pubitemid 43825607)
55. Vasa-Nicotera M, Brouilette S, Mangino M, Thompson JR, Braund P, Clemitson J, Mason A, Bodycote CL, Raleigh SM, Louis E, Samani NJ. Mapping of a major locus that determines telomere length in humans. Am. J. Hum. Genet. 2005;76:147-151. (Pubitemid 40023773)
56. Schroder CP, Wisman GB, de Jong S, van der Graaf WT, Ruiters MH, Mulder NH, de Leij LF, van der Zee AG, de Vries EG. Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Brit J Cancer 2001;84:1348-1353. (Pubitemid 32522103)
57. Zhang RG, Zhang RP. Effects of cisplatinum on telomerase activity and telomere length in BEL-7404 human hepatoma cells. Cell Res 2002;12:56-62.
58. Fishel ML, Vasko MR, Kelley MR. DNA repair in neurons: so if they don't divide what's to repair? Mutat. Res. 2007;614:24-36. (Pubitemid 44920332)
59. Flanary BE, StreitWJ. Progressive telomere shortening occurs in cultured rat microglia, but not astrocytes. Glia 2004;45:75-88. (Pubitemid 38076230)
60. Yaffe K, Lindquist K, Kluse M, Cawthon R, Harris T, Hsueh W-C, Simonsick EM, Kuller L, Li R, Ayonayon HN, Rubin SM, Cummings SR. Telomere length and cognitive function in community-dwelling elders: findings fromthe healthABC study. Neurobiol Aging 2011;32(11):2055-2060.
61. Valdes AM, Deary IJ, Gardner J, Kimura M, Lu X, Spector TD, Aviv A, Cherkas LF. Leukocyte telomere length is associated with cognitive performance in healthy women. Neurobiol Aging 2010;31:986-992.
62. Martin-RuizC, DickinsonHO, Keys B, RowanE,KennyRA,Von Zglinicki T. Telomere length predicts poststroke mortality, dementia, and cognitive decline. Ann Neurol 2006;60:174-180. (Pubitemid 44182392)
63. Caldecott KW. DNA single-strand breaks and neurodegeneration. DNA Repair 2004;3:875-882. (Pubitemid 38997929)
64. Abner CW, McKinnon PJ. The DNA double-strand break response in the nervous system. DNA Repair 2004;3:1141-1147. (Pubitemid 38997958)
65. Mariani EC, PM, Cherubini A, Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: An overview. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005;827:65-75. (Pubitemid 41551598)
66. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA,Markesbery WR. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 2005;64:1152-1156.
67. Blasiak J, Arabski M, Krupa R, Wozniak K, Rykala J, Kolacinska A, Morawiec Z, Drzewoski J, Zadrozny M. Basal, oxidative and alkylative DNA damage, DNA repair efficacy and mutagen sensitivity in breast cancer. Mutat Res 2004;554:139-148. (Pubitemid 39140822)
68. Nadin SB, Vargas-Roig LM, Drago G, Ibarra J, Ciocca DR. DNA damage and repair in peripheral blood lymphocytes from healthy individuals and cancer patients: A pilot study on the implications in response to chemotherapy. Cancer Lett 2006;239:84-87.
69. Kaya E, Keskin L, Aydogdu I, Kuku I, Bayraktar N, Erkut MA. Oxidant/antioxidant parameters and their relationship with chemotherapy in Hodgkin's lymphoma. J Int Med Res 2005;33:687-692. (Pubitemid 43009596)
70. Kennedy DD, Ladas EJ, Rheingold SR, Blumberg J, Kelly KM. Antioxidant status decreases in children with acute lymphoblastic leukemia during the first six months of chemotherapy. Pediat Blood Cancer 2005;44:378-385. (Pubitemid 40316031)
71. Caron JE,Krull KR,HockenberryM, JainN, KaemingkK,Moore IM. Oxidative stress and executive function in children receiving chemotherapy for acute lymphoblastic leukemia. Pediat Blood Cancer 2009;53:551-556.
72. Miketova P, Kaemingk K, HockenberryM, Pasvogel A, Hutter J, Krull K, Moore IM. Oxidative changes in cerebral spinal fluid phosphatidylcholine during treatment for acute lymphoblastic leukemia. Biol Res Nurs 2005;6:187-195. (Pubitemid 43920964)
73. Babiak RM, Campello AP, Carnieri EG, Oliveira MB.Methotrexate: pentose cycle and oxidative stress. Cell Biochem Funct 1998;16:283-293. (Pubitemid 28523763)
74. Girotti AW. Lipid hydroperoxide generation, turnover, and effector action in biological systems. J Lipid Res 1998;39:1529-1542. (Pubitemid 28377917)
75. Farooqui AA, Horrocks LA. Lipid peroxides in the free radical pathophysiology of brain disease. Cell Mol Neurobiol 1998;18:599-608. (Pubitemid 29012939)
76. Moore IM, Miketova P, Hockenberry M. Methotrexate-induced alterations in beta-oxidation correlate with cognitive abilities in children with acute lymphoblastic leukemia. Biol Res Nurs 2008;9:311-319.
77. Joshi G, Sultana R, Tangpong J, Cole MP, St. Clair DK, Vore M, Estus S, Butterfield DA. Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: Insight into chemobrain. Free Radical Res 2005;39:1147-1154. (Pubitemid 41601416)
78. Joshi G, Hardas S, Sultana R, St. Clair DK, Vore M, Butterfield DA. Glutathione elevation by gamma-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brainmediated by in vivo administration of adriamycin: Implication for chemobrain. J Neurosci Res 2007;85:497-503.
79. Tarumi W, Suzuki N, Takahashi N, Kobayashi Y, Kiguchi K, Sato K, Ishizuka B. Ovarian toxicity of paclitaxel and effect on fertility in the rat. J Obstet Gynaecol Res 2009;35:414-420.
80. Henderson VW, Paganini-HillA, Emanuel CK,DunnME, Buckwalter JG. Estrogen replacement therapy in older women: Comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 1994;51:896-900. (Pubitemid 24286044)
81. Robinson D, Friedman L, Marcus R, Tinklenberg J, Yesavage J. Estrogen replacement therapy and memory in older women. J Am Geriatr Soc 1994;42:919-922. (Pubitemid 24280363)
82. Sherwin BB, Gelfand MM. Sex steroids and affect in the surgical menopause: A double-blind, cross-over study. Psychoneuroendrocrinology 1985;10:325-335. (Pubitemid 16237741)
83. Sherwin BB. Hormones, mood, and cognitive functioning in post-menopausal women. Obstet Gynecol 1996;87(2 Suppl):20S-26S.
84. Kritz-Silverstein D, Barrett-Connor E. Hysterectomy, oophorectomy, and cognitive function in older women. J AmGeriatr Soc 2002;50:55-61. (Pubitemid 34053023)
85. Hao J, Rapp PR, Leffler AE, Leffler SR, Janssen WGM, Lou W, McKay H, Roberts JA, Wearne SL, Hof PR, Morrison JH. Estrogen alters spine number and morphology in prefontal cortex of aged female rhesus monkeys. J Neurosci 2006;26:2571-2578. (Pubitemid 44699017)
86. Paganini-Hill A,Henderson VW. Estrogen deficiency and risk of Alzheimer's disease. Amer J Epid 1994;140:256-261. (Pubitemid 24231911)
87. Sherwin BB. Estrogen and cognitive function in women. Proc Soc Exper Biol Med 1998;217:17-22.
88. Luine VN. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exper Neurol 1985;89:484-490. (Pubitemid 15040918)
89. Unfer TC, Conterato GM, da Silva JC, Duarte MM, Emanuelli T. Influence of hormone replacement therapy on blood antioxidant enzymes in menopausal women. Clinica Chimica Acta 2006;369:73-77. (Pubitemid 43783393)
90. Strehlow K, Rotter S, Wassmann S, Adam O, Groh́e C, Laufs K, B̈ohmM,NickenigG.Modulation of antioxidant enzyme expression and function by estrogen. Circ Res 2003;93:170-177. (Pubitemid 36919705)
91. Lee DC, Im JA, Kim JH, Lee HR, Shim JY. Effect of long-term hormone therapy on telomere length in postmenopausalwomen. Yonsei Med J 2005;46:471-479.
92. Benetos A, Okuda K, Lajemi M, Kimura M, Thomas F, Skurnick J, Labat C, BeanK, Aviv A. Telomere length as an indicator of biological aging: The gender effect and relation with pulse pressure and pulse wave velocity. Hypertension 2001;37:381-385. (Pubitemid 32198997)
93. Rahimian R, Chan L, Goel A, Poburko D, Van Breemen C. Estrogen modulation of endothelium-derived relaxing factors by human endothelial cells. Biochem Biophys Res Commun 2004;322:373-379. (Pubitemid 39490314)
94. Vasa M, Breitschopf K, Zeiher AM, Dimmeler S. Nitric oxide activates telomere and delays endothelial cell sensecence. Circ Res 2000;87:540-542.
95. Wilson CJ, Finch CE, Cohen HJ. Cytokines and cognition- the case for head-to-toe inflammatory paradigm. J Am Geriatr Soc 2002;50:2041-2056. (Pubitemid 35462453)
96. Maier SF,Watkins LR. Immune-to-central nervous system communication and its role in modulating pain and cognition: Implications for cancer and cancer treatment. Brain Behav Immun 2003;17:S125-S131. (Pubitemid 36298525)
97. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, Pollmacher T. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001;58:445-452. (Pubitemid 32411324)
98. Krabbe KS, Reichenberg A, Yirmiya R, Smed A, Pedersen BK, Bruunsgaard H. Low-dose endotoxemia and human neuropsychological functions. Brain Behav Immun 2005;19:453-460. (Pubitemid 41074784)
99. Tonelli LH, Postolache TT, Sternberg EM. Inflammatory genes and neural activity: Involvement of immune genes in synaptic function and behavior. Front Biosci 2005;10:675-680.
100. Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, SyedA, FritscheHA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004;25:94-102. (Pubitemid 38096266)
101. Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE, Duska LR, Fuller AF, Goodman AK, Nikrui N, MacNeill KM, Matulonis UA, Preffer FI, Seiden MV. Cytokines IL-1beta, IL-2, IL-6, IL-8,MCP-1, GM-CSF and TNF-alpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 2001;10:33-41. (Pubitemid 30219476)
102. Tsaavaris N, Kosmas C, Vadiaka M, Kanelopoulous P, Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Brit J Cancer 2002;87:21-27.
103. Plata-Salaman CR, French-Mullen JM. Interleukin-1 beta depresses calcium currents in CA1 hippocampal neurons at pathophysiological concentrations. Brain Res Bull 1992;29:221-223.
104. Ellison MD, Merchant RE. Appearance of cytokine-associated central nervous system myelin damage coincides temporally with serum tumor necrosis factor induction after recombinant interleukin-2 infusion in rats. J Neuroimmunol 1991;33:245-251.
105. Larson S, Dunn AJ. Behavioral effects of cytokines. Brain Behav Immun 2001;15:371-387. (Pubitemid 34044521)
106. Meyers CA, Valentine AD. Neurological and psychiatric adverse effects of immunological therapy. CNS Drugs 1995;3:56-68.
107. Kelley KW, Bluth́e R-M, Dantzer R, Zhou J-H, ShenW-H, Johnson RW, Broussard SR. Cytokine-induced sickness behavior. Brain Behav Immun 2003;17:112-118.
108. Cleeland CS, Bennett GJ, Dantzer R, Dougherty PM, Dunn AJ, Meyers CA, Miller AH, Payne R, Reuben JM, Wang XS, Lee BN. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? Cancer 2003;97:2919-2925.
109. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br JCancer 2002;87:21-27.
110. Meyers CA, Abbruzzese JL. Cognitive functioning in cancer patients: Effects of previous treatment.Neurology 1992;42:434-436.
111. Trask PC, Esper P, RibaM, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000;18:2316-2326. (Pubitemid 30350225)
112. Scheibel RS, Valentine AD, O'Brien S, Meyers CA. Cognitive dysfunction and depression during treatment with interferonalpha and chemotherapy. J Neuropsych Clin N 2004;16:185-191. (Pubitemid 38560902)
113. Ahles TA, Saykin AJ, Noll WW, Furstenberg CT, Guerin S, Cole B, Mott LA. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psycho-Oncology 2003;12:612-619. (Pubitemid 37086736)
114. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene:multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. 2000;97:3473-3478.
115. Jamroziak K, Robak T. Pharmacogenomics of MDR1/ABCB1 Gene: The influence on risk and clinical outcome of haematological malignancies. Hematology 2004;9:91-105. (Pubitemid 38697023)
116. Muramatsu T, Johnson DR, Finch RA, Johnson LK, Leffert JJ, Lin ZP, Pizzorno G, Sartorelli A. Age-related differences in vincristine toxicity and biodistribution in wild-type and transporter-deficient mice. Oncol Res 2004;14:331-343. (Pubitemid 39070674)
117. Pang PT, Lu B. Regulation of late-phase LTP and long-term memory in normal and aging hippocampus: Role of secreted proteins tPA and BDNF. Ageing Res Rev 2004;3:407-430. (Pubitemid 39487898)
118. Savitz J, Solms M, Ramesar R. The molecular genetics of cognition: dopamine, COMT and BDNF. Genes, Brain and Behavior 2006;5:311-328. (Pubitemid 43794814)
119. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, BertolinoA, ZaitsevE,GoldB,GoldmanD, DeanM, LuB,Weinberger DR. The BDNF val66met polymorphism affects activitydependent secretion of BDNF and human memory and hippocampal function. Cell 2003;112:257-269. (Pubitemid 36144114)
120. Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 2003;23:6690-6694. (Pubitemid 36951196)
121. Pezawas L, Verchiniski BA, Mattay VS, Callicott JH, Kolachana BS, Straub RE, Egan MF, Meyer-Lindenberg A, Weinberger DR. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci 2004;24:10099-10102. (Pubitemid 39492034)
122. Malhotra AK, Kestler LJ, Mazzanti C, Bates JA, Goldberg T, Goldman D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 2002;159:652-654. (Pubitemid 34274949)
123. Fardell J, Vardy J, Shah J, Johnston I. Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity. Psychopharmacology 2011; in press.
124. Aluise CD,Miriyala S, Noel T, Sultana R, Jungsuwadee P, Taylor TJ, Cai J, Pierce WM, Vore M, Moscow JA, St Clair DK, Butterfield DA. 2-Mercaptoethane sulfonate prevents doxorubicininduced plasma protein oxidation and TNF-α release: Implications for the reactive oxygen species-mediated mechanisms of chemobrain. Free Radical Bio Med 2011;50:1630-1638.
125. Wefel JS, Vardy J, Ahles T, Schagen SB. International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. The Lancet Oncol 2011;12:703-708.
126. de Jong N, Candel MJ, Schouten HC, Abu-Saad HH, Courtens AM. Course of mental fatigue and motivation in breast cancer patients receiving adjuvant chemotherapy. Ann Oncol 2005;16:372-382. (Pubitemid 40458312)
127. Tchen N, Juffs HG, Downie FP, Yi Q-L, Hu H, Chemerynsky I, Clemons M, Crump M, Goss PE, Warr D, Tweedale ME, Tannock IF. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003;21:4175-4183. (Pubitemid 46606186)
128. Hermelink K, Henschel V, Untch M, Bauerfeind I, Lux MP, Munzel K. Short term effects of treatment induced hormonal changes on cognitive function in breast cancer patients. Cancer 2008;113:2431-2439.
129. Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psycho- Oncology 2004;13:61-66. (Pubitemid 38139358)
130. Schilder CM, Eggens PC, Seynaeve C, Linn SC, Boogerd W, Gundy CM, Beex LV, Van Dam FS, Schagen SB. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: Cross-sectional findings from the neuropsychological TEAMside study. Acta Oncol 2009;48:76-85.
131. Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S. Cognitive effects of hormonal therapy in early stage breast cancer patients: A prospective study. Psycho-Oncology 2009;18:811-821.